GLP-1 patches for weight loss: what the evidence actually shows

What did @millennialrx actually say?

Ethan, a pharmacist, reviewed GLP-1 patches being sold on TikTok Shop for around $8 and called them a scam. His core argument: real GLP-1 medications require a prescription, cost far more than $8, and the molecules themselves are too large to cross skin. He said the patches contain "all just natural supplements" and concluded, "if you see any of these products claiming to be GLP-1 patches, it is a scam."

He also correctly named semaglutide, tirzepatide, and liraglutide as prescription GLP-1 receptor agonists and explained that GLP-1 is a naturally occurring hormone in the body that these drugs mimic or amplify. The overall message was clear and consumer-protective: cheap OTC patches are not a substitute for prescription GLP-1 therapy.

Does the science back this up?

Yes, on every major point. The molecular weight argument is well-established in pharmacokinetics literature. Peptide-based drugs like semaglutide have molecular weights exceeding 4,000 daltons. The general cutoff for passive transdermal absorption is around 500 daltons, sometimes called the "500 Dalton rule" (Bos and Meinardi, 2000, Experimental Dermatology).

Semaglutide specifically has a molecular weight of approximately 4,114 Da. Tirzepatide is even larger at roughly 4,813 Da. Neither can passively diffuse through intact skin. That is not a theoretical concern, it is basic biophysics. No peer-reviewed study has demonstrated effective transdermal delivery of any GLP-1 receptor agonist. The FDA has approved semaglutide only as a subcutaneous injection (Ozempic, Wegovy) and as an oral tablet with a specific absorption enhancer (Rybelsus), which works in the GI tract, not through skin. There is no FDA-approved transdermal GLP-1 formulation as of 2025.

What did they get wrong (or right)?

Ethan got the science right. But there is one minor slip worth flagging. He mispronounced or misspoke "tirzepatide" as "tersepartite" and referenced "blue tide," which appear to be verbal stumbles rather than factual errors. He also mentioned "true licity" likely meaning Trulicity (dulaglutide), which is accurate as a GLP-1 receptor agonist, though it is primarily used for type 2 diabetes rather than weight loss.

One nuance he did not address: researchers are actively studying microneedle patch technology as a potential future delivery method for peptide drugs, including GLP-1 agonists. Studies like Chen et al. (2022, Advanced Materials) have explored dissolving microneedle arrays for peptide delivery in preclinical models. This does not validate the $8 TikTok patches, which contain no GLP-1 compounds at all. But it means "transdermal GLP-1" is not pure fantasy in every research context. The products Ethan reviewed are still absolutely a scam. The distinction just matters for scientific precision.

What should you actually know?

The supplement ingredients in these patches, things like berberine, chromium, or green tea extract, are not GLP-1 receptor agonists. Some supplements like berberine have modest evidence for blood sugar support (Yin et al., 2008, Metabolism), but that is a completely different mechanism and a much smaller effect size than prescription GLP-1 therapy.

Calling a product a "GLP-1 patch" when it contains no GLP-1 agonist compounds is misleading marketing at best and consumer fraud at worst. The FTC has increased scrutiny on weight loss product claims, and the FDA has issued warnings about unapproved weight loss products sold online. If you are considering GLP-1 therapy for weight management or type 2 diabetes, the only evidence-based options are FDA-approved injectable or oral formulations prescribed and monitored by a licensed clinician. No patch, supplement, or $8 TikTok product changes that reality.